Read by QxMD icon Read


Marta Karpinski, Gabriella Francesca Mattina, Meir Steiner
No abstract text is available yet for this article.
November 28, 2016: Neuroendocrinology
Clemens Reuther, Vera Heinzle, Svenja Nölting, Sabine Herterich, Stefanie Hahner, Ensar Halilovic, Sébastien Jeay, Jens U Wuerthner, Elke Tatjana Aristizabal Prada, Gerald Spöttl, Julian Maurer, Christoph J Auernhammer
No abstract text is available yet for this article.
November 21, 2016: Neuroendocrinology
Yayoi Ikeda, Ayako Tagami, Munekazu Komada, Mifumi Takahashi
No abstract text is available yet for this article.
November 21, 2016: Neuroendocrinology
Kristie Conde, Carolina Fabelo, William C Krause, Robert Propst, Jordan Goethel, Daniel Fischer, Jin Hur, Cecilia Meza, Holly A Ingraham, Edward J Wagner
No abstract text is available yet for this article.
November 21, 2016: Neuroendocrinology
Eleonora S Pagano, Eduardo Spinedi, Juan J Gagliardino
No abstract text is available yet for this article.
November 16, 2016: Neuroendocrinology
Katarina Edfeldt, Kosmas Daskalakis, Christofer Bäcklin, Olov Norlén, Eva Tiensuu Janson, Gunnar Westin, Per Hellman, Peter Stålberg
Small intestinal neuroendocrine tumors (SI-NETs) are amine- and peptide producing neoplasms. Most patients display metastases at the time of diagnosis, they have an unpredictable individual disease course and the tumors are often therapy resistant. Chromogranin A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA) are the clinically most used biomarkers today, but there is a great need for novel diagnostic and prognostic biomarkers and new therapeutic targets. Sixty-nine biomarkers were screened in serum from 23 SI-NET patients and 23 healthy controls using multiplex PLA (proximity ligation assay)...
November 9, 2016: Neuroendocrinology
Jennifer W Hill, Latrice D Faulkner
No abstract text is available yet for this article.
October 11, 2016: Neuroendocrinology
Ismael González-García, Johan Fernø, Carlos Diéguez, Rubén Nogueiras, Miguel López
Hypothalamic lipid metabolism plays a major role in the physiological regulation of energy balance. Modulation of several enzymatic activities that control lipid biosynthesis, such as fatty acid synthase (FAS) and AMP-activated protein kinase (AMPK), impacts both feeding and energy expenditure. However, lipids can also cause pathological alterations in the hypothalamus. Lipotoxicity is promoted by excess lipids in tissues non suitable for their storage. A large amount of evidence has demonstrated that lipotoxicity is a pathophysiological mechanism leading to metabolic diseases, such as insulin resistance, cardiomyopathy, atherosclerosis and steatohepatitis...
October 11, 2016: Neuroendocrinology
Christopher J Marshall, Elodie Desroziers, Timothy McLennan, Rebecca E Campbell
No abstract text is available yet for this article.
October 7, 2016: Neuroendocrinology
Michael Deuschle, Ulrike Gotthardt, Ulrich Schweiger, Michael Dettling, Florian Holsboer, Isabella Heuser
Animal studies suggest that repeated episodes of elevated glucocorticoids lead to a dysregulation of the hypothalamus-pituitary-adrenal (HPA) system at a supra-pituitary level, and to impaired mnemonic function. We compared cognitive tests and both, feedback integrity and stress responsivity of the HPA system, between 11 elderly, male marathon runners - a model of repeated HPA system activation - and 10 sedentary controls. Marathon runners had significantly increased baseline, stress and post-stress ACTH, but not cortisol concentrations...
September 28, 2016: Neuroendocrinology
Ruth I Versteeg, Karin E Koopman, Jan Booij, Mariëtte T Ackermans, Unga A Unmehopa, Eric Fliers, Susanne E la Fleur, Mireille J Serlie
BACKGROUND: Altered brain dopaminergic and serotonergic pathways have been shown in obese rodents and humans, but it is unknown whether this is related to obesity per se or to the metabolic derangements associated with obesity. METHODS: We performed a case-control study in insulin sensitive obese (ISO) and insulin resistant obese (IRO) subjects (n = 12) and age-matched lean controls (n = 8) and measured serotonin transporter (SERT) binding in the whole diencephalon and specifically in the hypothalamus, as well as dopamine transporter (DAT) binding in the striatum using 123I-FP-CIT single photon emission computed tomography (SPECT)...
September 14, 2016: Neuroendocrinology
Sanne E Franck, Linda Broer, Aart Jan van der Lely, Peter Kamenicky, Ignacio Bernabéu, Elena Malchiodi, Patric J D Delhanty, Fernando Rivadeneira, Sebastian J C M M Neggers
BACKGROUND: The common exon 3 deletion polymorphism of the growth hormone receptor (d3-GHR) is associated with disease severity in acromegaly patients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating severe acromegaly. Response to PEGV treatment seems to be influenced by d3-GHR and appears to be more responsive to PEGV, although available results remain conflicting. OBJECTIVE: To assess the influence of d3-GHR on the responsiveness of acromegaly patients to PEGV by compiling the evidence derived from the largest available studies...
August 12, 2016: Neuroendocrinology
Helma Freitag, Friederike Christen, Florentine Lewens, Irina Grass, Franziska Briest, Sara Iwaszkiewicz, Britta Siegmund, Patricia Grabowski
INTRODUCTION: Characteristic clinical heterogeneity and mostly slow-growing behavior of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) cause problems in finding appropriate treatments. Thus, current therapy options are not satisfactory. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2. AIM: We assessed the effects of PKI-587 in different GEP-NEN tumor models, including poorly differentiated cell line LCC-18, compared with the established mTORC1 inhibitor everolimus...
August 12, 2016: Neuroendocrinology
Sven C Mueller, Lionel Landré, Katrien Wierckx, Guy T'Sjoen
BACKGROUND: To date, research findings are inconsistent about whether neuroanatomy in transgender persons resembles that of their natal sex or their gender identity. Moreover, few studies have examined the effects of long-term, cross-sex hormonal treatment on neuroanatomy in this cohort. The purpose of the present study was to examine neuroanatomical differences in transgender persons after prolonged cross-sex hormone therapy. METHODS: Eighteen transgender men (female-to-male), 17 transgender women (male-to-female), 30 non-transgender men (natal men), and 27 non-transgender women (natal women) completed a high-resolution structural MRI scan at 3Tesla...
August 5, 2016: Neuroendocrinology
Claudia Fischer, Tanja Mueller, Martina Pfeffer, Helmut Wicht, Charlotte von Gall, Horst-Werner Korf
BACKGROUND/METHODS: Melatonin, the neurohormone for darkness, mediates photoperiod dependent changes in physiology and behavior by targeting specific membrane bound receptors (MT1 and MT2). In the present study, we investigated the impact of MT1 receptor-deficiency on feeding behavior, locomotor activity and mRNA expression levels encoding for the polypeptide Pomc and neuropeptide Y (Npy) in the hypothalamic arcuate nucleus (ARC) and the adenohypophysis (pars distalis, PD and pars intermedia, PI) in a comparison between wild-type (WT) and MT1-deficient (MT1-/-) mice...
August 5, 2016: Neuroendocrinology
Sanne E Franck, Federico Gatto, Aart Jan van der Lely, Joseph A M J L Janssen, Alof H G Dallenga, A Paul Nagtegaal, Leo J Hofland, Sebastian J C M M Neggers
BACKGROUND: Growth hormone secreting pituitary adenomas (somatotroph adenoma) predominantly express somatostatin receptors (SSTRs) subtypes 2 and 5. Higher SSTR2 expression on somatotroph adenomas results in a better response to somatostatin analogues (SSAs), which preferentially bind, but also down regulate, SSTR2. The effect of the combined treatment with SSAs and the GH receptor antagonist pegvisomant (PEGV) on SSTR expression in somatotroph adenomas is currently unknown. AIM OF THE STUDY: To assess SSTR2 and SSTR5 expression in three groups of somatotroph adenomas: drug-naive, treated with long-acting (LA) SSA monotherapy, or LA-SSA/PEGV combination therapy before surgery...
July 25, 2016: Neuroendocrinology
Marcela Vargas Trujillo, Bruna Kalil, Suresh Ramaswamy, Tony M Plant
The aim of this immunohistochmical study was to evaluate the distribution of kisspeptin neurons in the pre-optic area (POA) of gonadally intact adult male and female rhesus monkeys, and to determine whether imposition of an estradiol (E2) positive feedback signal in the castrate male increased kisspeptin in the POA. Additionally, kisspeptin in POA of the intact female was examined during an LH surge induced prematurely by E2 administered in the early follicular phase. The number of kisspeptin neurons in POA of males and females was similar...
July 25, 2016: Neuroendocrinology
Christina Dimopoulou, Sarah M Leistner, Marcus Ising, Harald J Schneider, Jochen Schopohl, Sandra Rutz, Robert Kosilek, Richard Frohner, Gunter K Stalla, Caroline Sievers
OBJECTIVE: Diagnosis of acromegaly is delayed up to 10 years after disease onset despite obvious external/objective changes such as bone and soft-tissue deformities. We hypothesized that a lack of subjective perception of the disease state, possibly mediated by psychiatric or cognitive alterations, might contribute to the delayed initiation of a diagnostic work-up. DESIGN: Cross-sectional study. METHODS: We investigated perceived body image by standardized questionnaires (FKB-20: Fragebogen zum Körperbild; FBeK: Fragebogen zur Beurteilung des eigenen Körpers) in 81 acromegalic patients and contrasted them to a) a clinical control group of 60 patients with non-functioning pituitary adenomas (NFPA) who lack severe facial and physical alterations and b) healthy controls...
July 25, 2016: Neuroendocrinology
Jean-Yves Scoazec, Anne Couvelard, Geneviève Monges, Serge Guyétant, Segolène Bisot-Locard, Xavier Parot, Côme Lepage
INTRODUCTION: Many changes have recently occurred in the practice of NET pathology. We therefore aimed to evaluating how pathologists have adapted their daily practice to the most recent international guidelines for diagnostic and prognostic evaluation. PROCEDURES: A 12-month prospective study (PRONET) was carried out among French pathologists between August 2010 and July 2011. Data were collected using an anonymous electronic case report form. OBSERVATIONS: 500 laboratories were invited, 149 accepted to participate, 80 were active and 59 provided eligible cases...
July 21, 2016: Neuroendocrinology
Di Yu, Justyna Leja-Jarblad, Angelica Loskog, Per Hellman, Valeria Giandomenico, Kjell Oberg, Magnus Essand
Cancer immunotherapy is becoming a cornerstone in the clinical care of cancer patients due to the breakthrough trials with immune checkpoint blockade antibodies and chimeric antigen receptor T cells. The next breakthrough in cancer immunotherapy is likely to be oncolytic viruses engineered to selectively kill tumor cells and deceive the immune system to believe that the tumor is a foreign entity that needs to be eradicated. We have developed AdVince, an oncolytic adenovirus for treatment of liver metastases from neuroendocrine tumor (NET)...
July 21, 2016: Neuroendocrinology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"